Krishna Vaddi bought $466K of Prelude Therapeutics (PRLD)

Executed Mar 25 2025, disclosed Mar 27 2025, 2 days later.

Value, as filed

$466K

675,000 sh × $0.69

Executed

Mar 25 2025

the trade date, as filed

Disclosed

Mar 27 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+43.0%

+16.2% from execution

Over the 21 trading sessions from the disclosed entry session (Mar 27 2025), the stock returned +43.0% (delay-adjusted); from the execution session (Mar 25 2025), +16.2%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

KV Krishna Vaddi CEO profile →

Krishna Vaddi (CEO) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in PRLD. Across 1 priced purchase filing, the average 21-session return was +16.2% from execution and +43.0% from disclosure (delay-adjusted; derived). The largest single filing was $466K of PRLD (675,000 sh × $0.69, as filed), executed Mar 25 2025.

The name

PRLD PRLD PRLD · 3 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→